证券代码：603217 证券简称：元利科技 公告编号：2025-018 元利化学集团股份有限公司 关于召开2024年年度股东大会的通知 一、 召开会议的基本情况 (一)股东大会类型和届次 2024年年度股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 5 月 16 日 14 点 30 分 召开地点：潍坊市昌乐县朱刘街道工业园公司会议室 股东大会召开日期：2025年5月16日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (五)网络投票的系统、起止日期和投票时间。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 16 日 至2025 年 5 月 16 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15- ...

证券代码：603217 证券简称：元利科技 公告编号：2025-008 元利化学集团股份有限公司 第五届监事会第五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 元利化学集团股份有限公司（以下简称"公司"）第五届监事会第五次会议 于 2025 年 4 月 24 日以现场及通讯表决方式召开。会议通知于 2025 年 4 月 14 日以电话及电子邮件方式通知全体监事。会议应参加监事 3 人，实际参加表决监 事 3 人。会议由监事会主席黄维君先生召集并主持，董事会秘书列席了本次会议。 会议的召开符合《公司法》及《公司章程》的规定，形成的决议事项合法、有效。 本议案尚需提交 2024 年年度股东大会审议。 （三）审议通过了《关于<公司 2024 年年度报告及其摘要>的议案》 监事会认为：公司《2024 年年度报告》及其摘要的编制和审议程序符合法 律法规、中国证监会及上海证券交易所有关规定的要求，报告内容能够真实、准 确、完整地反映出公司报告期经营管理和财务状况，不存在任何虚假记载、误导 性 ...

证券代码：603217 证券简称：元利科技 公告编号：2025-007 元利化学集团股份有限公司 第五届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 元利化学集团股份有限公司（以下简称"公司"）第五届董事会第六次会议 于 2025 年 4 月 24 日以现场及通讯表决方式召开。会议通知于 2025 年 4 月 14 日以电话及电子邮件方式通知全体董事。会议应参加董事 9 人，实际参加董事 9 人。会议由董事长刘修华先生召集并主持，公司监事及高级管理人员列席了本次 会议。会议的召开符合《公司法》及《公司章程》的规定，形成的决议事项合法、 有效。 二、董事会会议审议情况 （一）审议通过了《关于<公司 2024 年度董事会工作报告>的议案》 表决结果：9 票同意，0 票反对，0 票弃权。 本议案尚需提交 2024 年年度股东大会审议。 （二）审议通过了《关于<公司 2024 年度总经理工作报告>的议案》 表决结果：9 票同意，0 票反对，0 票弃权。 （三）审议通过了《关于< ...

元利化学集团股份有限公司 证券代码：603217 证券简称：元利科技 公告编号：2025-013 关于2024年年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 分配比例：每 10 股派发现金红利 3.50 元（含税）。 本次利润分配拟以实施权益分派股权登记日总股本扣减当日公司回购专 用证券账户中的股份数为基数，具体日期将在权益分派实施公告中明确。在实施 权益分派的股权登记日前公司总股本发生变动的，拟维持每股分配比例不变，相 应调整分配总额，并将在相关公告中披露。 公司不存在触及《上海证券交易所股票上市规则》第 9.8.1 条第一款第 （八）项规定的可能被实施其他风险警示的情形。 一、公司 2024 年度利润分配预案 （一）2024 年度利润分配预案的具体内容 公司拟向全体股东每 10 股派发现金红利 3.50 元（含税）。截至 2025 年 3 月 31 日，公司总股本 208,087,600 股，扣减公司回购专用证券账户中的 2,880,000 股后的基数为 205,207,60 ...

证券代码：603217 证券简称：元利科技 公告编号：2025-017 元利化学集团股份有限公司 关于提请股东大会授权董事会办理以简易程序向特 定对象发行股票相关事宜的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 元利化学集团股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开 第五届董事会第六次会议、第五届监事会第五次会议，审议通过了《关于提请股 东大会授权董事会办理以简易程序向特定对象发行股票相关事宜的议案》。根据 《上市公司证券发行注册管理办法》（以下简称《注册管理办法》）等相关规定， 公司董事会提请股东大会授权董事会决定向特定对象发行融资总额不超过人民 币 3 亿元且不超过最近一年末净资产 20%的股票，授权期限为 2024 年年度股东 大会通过之日起至 2025 年年度股东大会召开之日止。上述事项尚需提交公司 2024 年年度股东大会审议。 一、本次授权的具体内容 （一）确认公司是否符合以简易程序向特定对象发行股票的条件 授权董事会根据《中华人民共和国公司法》《中华人民共和国证券法》《 ...

Financial Performance - The company's operating revenue for 2024 was CNY 2,219,571,289.46, representing a 1.75% increase compared to CNY 2,181,297,295.19 in 2023[26] - The net profit attributable to shareholders of the listed company decreased by 17.04% to CNY 207,129,052.62 from CNY 249,679,653.29 in the previous year[26] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 198,954,075.52, a decrease of 1.78% from CNY 202,567,212.99 in 2023[26] - The total profit for the period was ¥239,821,679.13, while the net profit attributable to shareholders was ¥207,129,052.62, a decrease of 17.04% year-on-year[50] - The company's net assets attributable to shareholders increased by 3.34% to ¥3,283,561,986.50 compared to the previous year[50] - Basic and diluted earnings per share decreased by 16.53% to ¥1.01 from ¥1.21 in the previous year[28] - The weighted average return on equity decreased by 1.68 percentage points to 6.43%[28] Dividend and Share Repurchase - The company plans to distribute a cash dividend of CNY 3.50 per 10 shares, totaling CNY 71,822,660.00, which accounts for 34.68% of the net profit attributable to shareholders[8] - The total amount spent on cash dividends and share repurchases was CNY 110,837,318.00, representing 53.51% of the net profit attributable to shareholders[8] - The company repurchased a total of 2,450,000 shares during the year, with a total payment of CNY 39,014,658.00[8] - The total cash dividend amount (including tax) for the last three accounting years is CNY 258,395,452, with an average net profit of CNY 308,711,242.65, resulting in a cash dividend ratio of 83.70%[142] - The company has established a cash dividend policy that mandates a minimum cash distribution of 15% of the distributable profit when there are no major investment plans or cash expenditures[140] Operational Efficiency - The net cash flow from operating activities decreased by 28.94% to ¥46,803,272.13 compared to the previous year[27] - The decrease in net cash flow from operating activities was attributed to a reduction in tax refunds received[29] - The operating costs rose by 3.45% to ¥1,845,251,927.41, indicating a higher cost structure[52] - Research and development expenses increased by 3.19% to ¥94,152,537.00, reflecting ongoing investment in innovation[52] - The company is focusing on deepening supplier cooperation to reduce raw material costs and improve production efficiency[49] Market and Product Development - The company achieved significant growth in core products such as mixed dibasic acid dimethyl ester and fatty alcohol, with new products like PCDL and bio-based BDO gaining increasing customer recognition[40] - The company is expanding its market presence in hindered amine light stabilizers and biosynthetic sectors, emphasizing multi-channel marketing strategies to meet customer needs[104] - The company has developed and achieved mass production of bio-based BDO, reducing reliance on traditional fossil resources[85] - The company aims to achieve high-quality development by focusing on customer-centricity, market orientation, innovation, and talent enhancement by 2025[104] Research and Development - The company obtained 2 new authorized invention patents and applied for 5 new patents during the reporting period, demonstrating its commitment to technological innovation[41] - The company has completed over 30 technology research projects in collaboration with various research institutes, highlighting its commitment to R&D[85] - The company has a total of 149 R&D personnel, representing 13.86% of the total workforce, with a majority holding bachelor's degrees[67] - Continuous R&D investment is prioritized to enhance existing product processes and accelerate new product development, leveraging AI technology for innovation[104] Environmental and Safety Management - The company emphasizes environmental protection, with its dibasic acid dimethyl ester series products replacing harmful solvents and meeting low-carbon development requirements[46] - The company has implemented a comprehensive wastewater treatment system, ensuring no wastewater was discharged externally in 2024[151] - The company has established emergency response plans for environmental incidents, with successful drills conducted to test the feasibility and reliability of these plans[161] - The company adheres to multiple environmental standards, including the "Shandong Province Boiler Air Pollutant Emission Standards" and "Hazardous Waste Incineration Pollution Control Standards"[154] Governance and Management - The company maintains a robust governance structure, ensuring compliance with relevant laws and regulations through regular board and shareholder meetings[110] - The company has undergone a restructuring of its board and supervisory committee, with new elections held in August 2024[122] - The company’s management structure has seen significant changes, with multiple appointments and resignations reflecting ongoing strategic adjustments[121] - The company has a total of 1,075 employees, with 125 in the parent company and 950 in major subsidiaries[131] Risk Management - There are no significant risks identified that could adversely affect the company's future development strategy and operational goals[11] - The company faces market competition risks, particularly if market growth lags behind supply growth, which could impact revenue and profitability[106] - Safety production risks are present due to the use of hazardous chemicals, necessitating strict adherence to safety protocols to prevent accidents[107] Shareholder Commitments - The controlling shareholder Liu Xiuhua and shareholders holding more than 5% of shares have committed to avoid any business competition with the company[171] - The company will minimize related party transactions and ensure fairness and legality in unavoidable transactions[173] - The company has committed to a 36-month lock-up period for major shareholders following the IPO, preventing them from transferring shares[168]

Revenue and Profit - Revenue for Q1 2025 was CNY 544,399,956.60, a decrease of 1.45% compared to CNY 552,407,605.55 in the same period last year[4] - Net profit attributable to shareholders was CNY 46,595,112.89, down 16.04% from CNY 55,495,434.10 year-on-year[4] - Basic and diluted earnings per share decreased by 18.52% to CNY 0.22 from CNY 0.27 in the previous year[4] - Operating profit for Q1 2025 is CNY 55,850,525.07, down 13.1% from CNY 64,545,483.96 in the same period last year[18] - The net profit for Q1 2025 is CNY 46,595,112.89, a decrease of 16.9% compared to CNY 55,495,434.10 in Q1 2024[18] - The total comprehensive income for Q1 2025 is CNY 46,566,530.34, down from CNY 55,403,981.92 in Q1 2024[19] - Basic and diluted earnings per share for Q1 2025 are both CNY 0.22, a decrease from CNY 0.27 in Q1 2024[19] Cash Flow and Operating Activities - Net cash flow from operating activities was negative at CNY -20,485,695.15, an improvement from CNY -62,735,354.93 in the same period last year[4] - Cash flow from operating activities in Q1 2025 shows a net outflow of CNY 20,485,695.15, an improvement from a net outflow of CNY 62,735,354.93 in Q1 2024[22] - Operating cash flow for Q1 2025 was $21,971,581.97, a significant improvement from a negative cash flow of -$139,841,607.94 in Q1 2024[32] - Total cash inflow from operating activities in Q1 2025 was $284,072,301.44, compared to $297,844,231.94 in Q1 2024, reflecting a decrease of approximately 4.3%[32] - Cash outflow for purchasing goods and services in Q1 2025 was $222,226,271.97, down from $429,244,796.27 in Q1 2024, indicating a reduction of about 48.3%[32] - The company generated CNY 128,171,722.24 from financing activities in Q1 2025, compared to CNY 98,893,888.88 in Q1 2024[23] - The company reported a cash outflow of $40,000,000.00 related to financing activities in Q1 2025[33] - The net increase in cash and cash equivalents for Q1 2025 was $21,686,518.68, contrasting with a decrease of -$141,249,994.37 in Q1 2024[33] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,306,517,055.28, a decrease of 0.83% from CNY 4,342,728,334.71 at the end of the previous year[5] - Current assets as of March 31, 2025, totaled RMB 2,637,600,371.33, a decrease from RMB 2,725,298,456.87 as of December 31, 2024[13] - Non-current assets increased to RMB 1,668,916,683.95 as of March 31, 2025, compared to RMB 1,617,429,877.84 as of December 31, 2024[14] - Total liabilities decreased to RMB 977,378,475.25 as of March 31, 2025, from RMB 1,059,166,348.21 as of December 31, 2024[14] - Shareholders' equity increased to RMB 3,329,138,580.03 as of March 31, 2025, compared to RMB 3,283,561,986.50 as of December 31, 2024[15] Expenses - Sales expenses increased by 42.50%, reflecting higher marketing costs during the period[7] - The company incurred R&D expenses of CNY 22,569,957.03 in Q1 2025, an increase of 21.0% from CNY 18,643,690.63 in Q1 2024[18] - The company reported a decrease in financial expenses, with interest expenses at CNY 2,027,503.88 compared to CNY 5,768.37 in the previous year[18] - The company's financial expenses for Q1 2025 were reported as CNY -4,582,310.50, compared to CNY -4,937,492.50 in Q1 2024, showing an improvement in financial costs[28] Accounts Receivable and Inventory - Accounts receivable increased by 48.68%, primarily due to an increase in receivables during the reporting period[7] - Accounts receivable rose to RMB 205,811,464.46 as of March 31, 2025, compared to RMB 138,427,620.79 as of December 31, 2024, reflecting an increase of 48.67%[13] - The company's accounts receivable increased from CNY 132,863,515.68 on December 31, 2024, to CNY 195,025,939.66 on March 31, 2025, an increase of approximately 46.9%[25] - The company's inventory decreased from CNY 41,230,298.86 on December 31, 2024, to CNY 36,962,598.47 on March 31, 2025, a reduction of about 10.3%[25] Cash and Cash Equivalents - Cash and cash equivalents were RMB 1,658,234,719.22 as of March 31, 2025, down from RMB 1,842,066,887.45 as of December 31, 2024[12] - The cash and cash equivalents at the end of Q1 2025 stand at CNY 1,407,234,719.22, down from CNY 1,263,461,504.21 at the end of Q1 2024[23] - The company's cash and cash equivalents decreased from CNY 699,055,467.25 on December 31, 2024, to CNY 591,534,612.88 on March 31, 2025, a decline of approximately 15.4%[25] - Cash and cash equivalents at the end of Q1 2025 totaled $340,534,612.88, up from $157,472,655.19 at the end of Q1 2024[33] Other Financial Metrics - The weighted average return on equity decreased to 1.41%, down from 1.73% in the previous year[5] - Total operating revenue for Q1 2025 was RMB 544,399,956.60, a decrease of 1.83% compared to RMB 552,407,605.55 in Q1 2024[17] - Total operating costs for Q1 2025 were RMB 488,273,815.34, down 1.01% from RMB 495,776,696.19 in Q1 2024[17] - Operating costs included RMB 451,394,256.31 in cost of goods sold for Q1 2025, a decrease of 2.82% from RMB 462,696,348.72 in Q1 2024[17]

元利化学集团股份有限公司 2024 年度独立董事述职报告 本人（姜宏青）作为元利化学集团股份有限公司（以下简称"公司"）的独 立董事，在任职期间严格按照《公司法》《证券法》《上市公司独立董事管理办 法》《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引 第 1 号——规范运作》及《公司章程》的规定，在 2024 年工作中，认真履行职 责，充分发挥独立董事的作用，恪尽职守，勤勉尽责，维护公司利益，维护全体 股东尤其是中小股东的利益，积极出席相关会议，对各项议案进行认真审议，充 分发挥独立董事及各专门委员会委员的作用。现将本人 2024 年度履职情况汇报 如下： 姜宏青，中国国籍，无境外永久居留权，1965 年 8 月出生，管理学博士， 中国注册会计师非执业会员，中国海洋大学管理学院教授。1985 年 7 月到 1993 年 9 月，任安徽财贸学院会计系教师；1993 年 10 月至今，任中国海洋大学管理 学院教师。2019 年 4 月至 2024 年 10 月任科创板上市公司恒誉环保（688309） 独立董事，2023 年 11 月至今任创业板上市公司泰和科技（300801）独立董事， 2020 ...

元利化学集团股份有限公司 2024 年度独立董事述职报告 本人（祁庆生）作为元利化学集团股份有限公司（以下简称"公司"）的独 立董事，在任期内严格按照《公司法》《证券法》《上市公司独立董事管理办法》 《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》及《公司章程》的规定，充分发挥专业优势，忠实、勤勉、独 立地履行独立董事职责，积极参与公司重大事项决策，客观、公正、审慎地发表 意见，为董事会的科学决策提供支撑，切实维护公司和全体股东特别是中小股东 的合法权益。现将本人 2024 年度履职情况汇报如下： 一、基本情况 （一）个人履历 祁庆生，男，1966 年出生，中国国籍，无境外居留权，分子微生物学研究 生学历、微生物学博士学位。现任山东大学生命科学院教授、公司独立董事。 （二）独立性说明 经自查，本人符合中国证监会《上市公司独立董事管理办法》《上海证券交 易所上市公司自律监管指引第 1 号——规范运作》中关于独立董事独立性的要求， 不存在影响独立性的情况。 二、独立董事年度履职情况 | 独立董事 | 参加董事会的情况 | | | | 参加股东大 会的情况 | | | -- ...

天职国际 2023 年度经审计的收入总额 31.97 亿元，审计业务收入 26.41 亿 元，证券业务收入 12.87 亿元。2023 年度上市公司审计客户 263 家，主要行业 （证监会门类行业，下同）包括制造业、信息传输、软件和信息技术服务业、电 力、热力、燃气及水生产和供应业、批发和零售业、交通运输、仓储和邮政业等， 审计收费总额 3.19 亿元，本公司同行业上市公司审计客户 158 家。 元利化学集团股份有限公司 董事会审计委员会对会计师事务所 2024 年度履行监督职责情况报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理 准则》《国有企业、上市公司选聘会计师事务所管理办法》《上海证券交易所上 市公司自律监管指引第 1 号——规范运作》和《公司章程》等规定和要求，元利 化学集团股份有限公司（以下简称"公司"）董事会审计委员会本着勤勉尽责的 原则，恪尽职守，认真履职。现将董事会审计委员会对会计师事务所 2024 年度 履行监督职责的情况汇报如下： 一、2024 年年审会计师事务所基本情况 （一）会计师事务所基本情况 天职国际会计师事务所（特殊普通合伙）（以下简称"天职国际"）创立 ...